Diligence memo · auto-generated · as of July 2, 2026
RedHill Biopharma Ltd.
RedHill Biopharma Ltd. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
RedHill Biopharma Ltd. operates in Pharmaceuticals, based in TEL AVIV.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
RedHill Biopharma Ltd. has raised $73M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $48M on 2019-10-22.
Most recent recorded round closed around 2024-01-25.
Valuation (modeled)modeled
Provath models RedHill Biopharma Ltd. at approximately $102M (range $32M–$164M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.18× the median modeled value of Series C Pharmaceuticals companies in 2022–2024 (30 peers) — value vs value, same stage and era. Issuer reports $5M–$25M revenue while modeled below niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 24 months.
Last raise 2.4 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 2.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 87% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 55% of those peers.
Closest niche peers: Vigil Neuroscience, Inc., Leap Therapeutics, Inc., Alimera Sciences Inc, VYNE Therapeutics Inc., Lusaris Therapeutics, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.